Background Salivary gland tumors (SGT) correspond to a heterogeneous group of lesions with variable biological behavior. The present study aimed to determine the distribution and demographic findings of salivary gland neoplasms in a northeast Brazilian population. Material and Methods A retrospective descriptive cross-sectional study was performed. A total of 588 cases of SGT were diagnosed between 2006 and 2016 of 4 pathology services in the state of Sergipe, Brazil. All cases were reviewed, and data such as sex, age, anatomical location, and histopathological diagnosis were collected. Results A total of 470 (79.9%) tumors were benign and 118 (20.1%) were malignant. The majority of the patients were females (n=328, 55.8%) with an overall female:male ratio of 1.2:1. The major salivary glands were affected more than the minor glands (69.5% vs. 30.5%). Pleomorphic adenoma (n=419, 71.3%) and mucoepidermoid carcinoma (n=29, 4.9%) were the most frequent benign and malignant tumors, respectively. In addition, both benign and malignant tumors occurred more frequently in the parotid gland (n=300, 51%, p <0.05). Conclusions The epidemiologic profile and clinical characteristics of SGT were similar to those described in other countries and other regions of Brazil. Epidemiological studies of SGT help to understand their clinical and pathological features and are essential to establish the proper management and prognosis. Key words: Salivary gland, tumors, epidemiology, head and neck pathology.
The low-level laser has proven successful in stimulating the production of collagen in wound healing assays. However, diversity has been observed in the protocols used. This work has evaluated the effects of three protocols of low-level laser therapy (LLLT) in the healing of open wounds in rats. Standard-sized wounds of 1 cm2 were performed with a scalpel in the middorsal region of 60 male Wistar rats weighing 225±25 g, and they were assigned into four groups (n=15): CTR (non-irradiated animals), LT1 (20 J/cm2 daily), LT2 (16 J/cm2 daily) and LT3 (20 J/cm2 daily). After 7, 14 and 21 days, five animals/day were euthanized and the wounds analyzed histologically. Data were subjected to normality analysis of distribution using Shapiro-Wilk test. Gaussian data were analyzed using ANOVA and Bonferroni tests whereas non-Gaussian data were analyzed using Kruskal-Wallis and Dunn tests, considering significant p values less than 0.05. The LLLT in all protocols reduced the inflammation and collagen deposition increased significantly (p<0.05). However, LT2 showed the highest levels of collagen in all phases of the study (p<0.05) induced faster replacement of immature collagen III by mature collagen I in the early stages of repair and early collagen remodeling promoted by providing better organization architectural beams deposited. It was concluded that all protocols induced an increase in collagen scar. However, the protocol 2 (16 J /cm2, daily application) promoted the most significant increases in collagen deposition, accelerated maturation of collagen and showed the best architecture of the final fibrous scarring.
Salivary gland tumors (SGT) represent an uncommon heterogeneous group of tumors with complex clinical and pathological characteristics. The prevalence of these lesions varies between studies but has been estimated between 3 and 6% of all tumors in the head and neck region. The present study aimed to evaluate the distribution and demographic findings of salivary gland tumors diagnosed in an oral pathology service in Mexico. A retrospective descriptive cross-sectional study was performed. A total of 164 cases of SGT from a private oral pathology service were diagnosed between 2000 and 2019 in Mexico City. All cases were reviewed histologically, and demographic data and histopathological diagnoses were collected. A total of 110 (67.1%) tumors were benign, and 54 (32.9%) were malignant. The majority of patients were female (n = 100, 61.0%) with an overall female:male ratio of 1.6:1. The minor salivary glands were affected more than the major salivary glands (68.9% vs. 25.6%). The palate (n = 67, 40.9%) was the most commonly affected site, followed by the parotid gland (n = 37, 22.6%), lips (n = 16, 9.8%), and buccal mucosa (n = 14, 8.5%). Pleomorphic adenoma (n = 88; 80.0%) and mucoepidermoid carcinoma (n = 16, 29.6%) were the most frequent benign and malignant tumors, respectively. The general features of SGT from the studied Mexican population shared some similarities and differences compared to previously reported series from various parts of the world.
Objective To report the clinicopathologic features of acquired oral syphilis cases in South American countries. Materials and Methods Clinical data were retrospectively collected from the records of 18 oral diagnostic services in Argentina, Brazil, Chile, Colombia, Venezuela, Uruguay, and Peru. Serologies of nontreponemal and treponemal tests were used for diagnosis. Results The series comprised 339 cases of acquired oral syphilis. Secondary syphilis ranked as the most common stage (86.7%). Lesions were more frequent among males (58.0%) and young adults with a mean age of 33.3 years. Individuals aged 20–29 years were most affected (35.3%). The most commonly involved sites were the tongue (31.6%), lip/labial commissure (25.1%), and hard/soft palate (20.4%). Clinically, acquired oral syphilis usually presented as mucous patches (28.4%), papules (25.7%), and ulcers (18.1%). Skin manifestations occurred in 67.7% of individuals, while lymphadenopathy and fever were observed in 61.3% and 11.6% of all subjects, respectively. Most patients were treated with the benzathine penicillin G antibiotic. Conclusion This report validates the spread of acquired oral syphilis infection among young adults in South America. Our directives include accessible diagnostic tools for proper disease screening, surveillance, and counselling of affected individuals, especially in low‐ and middle‐income countries.
Background: Oral focal mucinosis (OFM) is a rare benign condition of unknown etiology, considered the oral counterpart of cutaneous focal mucinosis. We report the clinicopathologic features of 21 cases of OFM in conjunction with a review of the literature. Methods: Clinical data were collected from the records of five oral and maxillofacial pathology services. All cases were evaluated by hematoxylin and eosin staining, histochemistry, and immunohistochemistry (vimentin, S-100, α-SMA, CD34, and mast cell). Results: The series comprised 14 females (66.7%) and seven males (33.3%), with a mean age of 48.2 ± 20.7 years (range: 8-77 years) and a 2:1 female-to-male ratio. Most of the lesions affected the gingiva (n = 6, 28.6%) and presented clinically as asymptomatic sessile or pedunculated nodules with fibrous or hyperplasic appearance. All cases were negative for S-100 protein, CD34, and α-SMA and positive for Alcian blue staining. Conservative surgical excision was the treatment in all cases, and there was only one recurrence. Conclusion: OFM is a rare benign disorder that is often clinically misdiagnosed as reactive lesions or benign proliferative processes. Dermatologists and pathologists should consider OFM in the differential diagnosis of soft tissue lesions in the oral cavity, mainly located in the gingiva. K E Y W O R D S connective tissue diseases, diagnosis, oral focal mucinosis, oral pathology 1 | INTRODUCTION Oral focal mucinosis (OFM) is considered to be the oral counterpart of cutaneous focal mucinosis (CFM) that likely develops due to an overproduction of hyaluronic acid by fibroblasts. 1-3 As a result, a well-demarcated myxomatous tissue positive for Alcian blue (pH 2.5) is observed microscopically; which may mimic other oral myxoid lesions, such as soft-tissue myxoma, fibrous hyperplasia with myxoid degeneration, nerve sheath myxoma (NSM), myxoid neurofibroma, and mucocele. 1
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.